Prevalence of Hemolytic Uremic Syndrome (HUS) in Pediatrics

Not yet recruiting

• Conditions: Prevalence of Hemolytic Uremic Syndrome

• Registration Number: NCT07171749
• Lead Sponsor: Assiut University

Brief Summary

To determine the prevalence of hemolytic uremic syndrome (HUS) among pediatric patients admitted to Assiut University Children's Hospital, and to describe the demographic, clinical, and laboratory characteristics of the affected population.

Detailed Description

Hemolytic uremic syndrome (HUS) is a rare but serious condition characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. \[1\] Two main subtypes of HUS are recognized. The majority of pediatric cases are classified as typical HUS, most frequently associated with Shiga toxin-producing Escherichia coli (STEC) infection. In contrast, atypical HUS (aHUS) is less common, accounting for approximately 5-10% of cases, and is linked to dysregulation of the complement system. The clinical course and prognosis differ significantly between these subtypes.\[2\].

Understanding the prevalence of HUS is critical for early recognition and timely intervention, especially in resource-limited settings. \[3\] Complications of HUS can be severe and include neurological manifestations, hypertension, persistent renal impairment, and in some cases, death. Early diagnosis and supportive care are critical for improved outcomes \[4\].

Local factors such as water safety, sanitation, access to early antibiotics, and public health surveillance greatly affect the observed prevalence. \[5\] The management of typical HUS caused by STEC is generally supportive. \[6\] For aHUS, early treatment is crucial to avoid end-stage renal disease (ESRD) and mortality. The cornerstones of treatment for aHUS are first-line therapy with eculizumab \[7\]

Study Timeline

• Status Verified: 2025-09
• Study First Submitted: 2025-09-06
• Study First Submitted QC: 2025-09-11
• Last Update Submitted: 2025-09-11
• Study First Posted: 2025-09-15
• Last Update Posted: 2025-09-15
• Study Start: 2025-10-01
• Primary Completion: 2026-09-30
• Study Completion: 2026-10-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Patients aged below 18 years at the time of diagnosis.
• Confirmed diagnosis of HUS based on the clinical triad (microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury).

Exclusion Criteria

• Patients aged 18 years or above at the time of diagnosis.
• Incomplete or missing medical records that do not confirm the diagnosis.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of Hemolytic Uremic Syndrome (HUS) among Pediatric Patients	Within 12months of enrollment (october 2025-September 2026)	The proportion of pediatric patients diagnosed with HUS out of the total number of children admitted to Assiut University Children's Hospital during the study period. Diagnosis will be based on clinical, laboratory, and imaging criteria.